FDA Approves Durvalumab for Limited-Stage SCLC

Durvalumab was associated with a 27% reduction in the risk for death compared with placebo in the phase 3 ADRIATIC trial.
Medscape Medical News

source https://www.medscape.com/viewarticle/fda-approves-durvalumab-limited-stage-sclc-2024a1000mhg?src=rss